LifeMD Earnings Call Transcripts
Fiscal Year 2026
-
A leading virtual care provider highlighted strong growth, high-margin pharmacy operations, and expanding specialty services, especially in GLP-1 metabolic health and women's health. Technology and insurance infrastructure are key differentiators, with 2024 guidance reaffirmed at $220M–$230M revenue and $12M–$17M EBITDA.
-
Q1 2026 saw revenue of $50.2M, record subscriber growth, and strong momentum in weight management and women's health. Gross margin expanded to 88%, and full-year guidance was reaffirmed, with profitability expected in the second half as acquisition costs decline.
Fiscal Year 2025
-
Delivered record Q4 and full-year results with 25% revenue growth, strong subscriber gains, and margin expansion. Aggressive investments in patient acquisition and AI-driven care are expected to drive 2026 revenue to $220–$230 million, with pharmacy and specialty care as key growth drivers.
-
Q3 2025 saw 13% revenue growth and 30% higher adjusted EBITDA, with strong telehealth and RexMD performance. Insurance enablement and new oral GLP-1 therapies are set to drive growth in 2026, while the company maintains a robust balance sheet and focuses on core virtual care.
-
Q2 2025 saw 23% revenue growth and a 560% jump in telehealth adjusted EBITDA, despite RexMD headwinds and higher weight management refunds. Guidance was revised lower, but new launches in behavioral and women's health, plus insurance expansion, position the business for long-term growth.
-
Q1 2025 saw 49% revenue growth and first positive GAAP net income, driven by strong telehealth and new service lines. Guidance for 2025 was raised, with continued expansion in Medicare, GLP-1 partnerships, and new health verticals expected to fuel growth.
Fiscal Year 2024
-
Q4 and full-year 2024 results exceeded guidance, with 43% revenue growth and strong telehealth and WorkSimpli performance. 2025 guidance projects continued double-digit growth, margin normalization, and new launches in behavioral health, insurance, and women's health.
-
Q3 saw 38% revenue growth and record gross margins, with telehealth revenue up 65% year-over-year and Adjusted EBITDA exceeding guidance. The company launched a national pharmacy, expanded payer contracts, and enhanced its weight management and men's health offerings.
-
Core telehealth business delivered 67% year-over-year revenue growth and achieved profitability ahead of schedule, driven by strong weight management performance and improved retention. WorkSimpli faced challenges but is expected to recover by year-end. Full-year revenue guidance was reiterated, with telehealth guidance raised and consolidated EBITDA guidance lowered due to WorkSimpli.